Physician profile
Gary Jones
NPI 1699753152
$871.02
in general payments reported to CMS, 2019-2025
9 companies · $93.57 in 2025
The $93.57 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $74.50 · 2022: $117 · 2023: $248 · 2024: $67.76 · 2025: $93.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $193.78 | 2023-2025 | Myfembree |
| Ferring Pharmaceuticals INC. | $167.13 | 2019-2023 | Menopur |
| Hologic Sales and Service, LLC | $128.70 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Fluent Fluid Management System |
| Emd Serono, INC. | $125.16 | 2019-2022 | |
| Abbvie INC. | $103.70 | 2019-2023 | |
| Coopersurgical, INC. | $48.70 | 2024-2025 | Stripper, Origio Sequential Fert |
| Galen US INC | $46.84 | 2019 | |
| Merck Sharp & Dohme LLC | $43.98 | 2019-2020 | |
| Pfizer INC. | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.